Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

European shares closed higher on Tuesday, buoyed by better-than-expected corporate earnings and renewed optimism that the ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

In June, Hims & Hers’ stock dropped over 30% following the breakdown of a brief partnership with Novo Nordisk. The ...

Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...